Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography.

  title={Imaging Kappa Opioid Receptors in the Living Brain with Positron Emission Tomography.},
  author={Michael S Placzek},
  journal={Handbook of experimental pharmacology},
  • Michael S Placzek
  • Published 7 August 2021
  • Biology, Medicine
  • Handbook of experimental pharmacology
Kappa opioid receptor (KOR) neuroimaging using positron emission tomography (PET) has been immensely successful in all phases of discovery and validation in relation to radiotracer development from preclinical imaging to human imaging. There are now several KOR-specific PET radiotracers that can be utilized for neuroimaging, including agonist and antagonist ligands, as well as C-11 and F-18 variants. These technologies will increase KOR PET utilization by imaging centers around the world and… 


Discrepancies in Kappa Opioid Agonist Binding Revealed through PET Imaging.
Changes in BPND were measured using kappa antagonists (naloxone, naltrexone, LY2795050, JDTic, nor-BNI), and it was found BPND was affected similarly between [11C]GR103545 and [ 11C]LY2459989, and kappa agonists salvinorin A and U-50488 caused dramatic reductions inBPND but did not change [11 C]LY 2459989 binding.
Human Positron Emission Tomography Neuroimaging.
The field of human PET neuroimaging is introduced, some of its conceptual underpinnings, and motivating questions are introduced, and some of the more recent advances in radiotracer development, quantitative modeling, and applications of PET to the study of the human brain are highlighted.
Novel Kappa Opioid Receptor Agonist as Improved PET Radiotracer: Development and in Vivo Evaluation.
The novel KOR agonist tracer 11C-FEKAP demonstrated binding specificity and selectivity in vivo and exhibited attractive properties of fast tissue kinetics and high specific binding.
Is There a Role for GPCR Agonist Radiotracers in PET Neuroimaging?
All existing PET radiotracers used from animals to humans and their role for understanding the ligand-receptor paradigm of GPCR in comparison with corresponding antagonist radiot Racers are reviewed.
Quantitative Rodent Brain Receptor Imaging
Challenges and advances of quantitative rodent brain imaging are reviewed to make the readers aware of its physical limitations, as well as to inspire them for its potential applications in preclinical research.
Development and In Vivo Evaluation of a κ-Opioid Receptor Agonist as a PET Radiotracer with Superior Imaging Characteristics
The development and evaluation of 11C-EKAP is reported, successfully developed, as a KOR agonist tracer with dual attractive imaging properties of fast uptake kinetics and high specific binding in vivo.
Synthesis and Evaluation of 11C-LY2795050 as a κ-Opioid Receptor Antagonist Radiotracer for PET Imaging
This newly developed KOR antagonist tracer has since been advanced to PET imaging of KOR in humans and constitutes the first successful KOR antagonists radiotracer.
Novel 18F-Labeled κ-Opioid Receptor Antagonist as PET Radiotracer: Synthesis and In Vivo Evaluation of 18F-LY2459989 in Nonhuman Primates
The evaluation of 18F-LY2459989 in nonhuman primates demonstrated many attractive imaging properties: fast tissue kinetics, specific and selective binding to the KOR, and high specific binding signals.
Social status and demographic effects of the kappa opioid receptor: a PET imaging study with a novel agonist radiotracer in healthy volunteers
There was an inverse correlation between social status and KOR levels that was largely specific to the reward/aversion areas of the brain, which suggests the KOR system may act as a mediator for the negative effects of social behaviors in humans.